Stay updated on Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Sign up to get notified when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    7 days ago
    Change Detected
    Summary
    The NCT03598608 page now displays the clinical-trial record, including its study design, eligibility criteria, locations, outcomes, and terminated status, where a 403 error page had appeared before.
    Difference
    77%
    Check dated 2026-11-08T04:30:46.000Z thumbnail image
  3. Check
    14 days ago
    Change Detected
    Summary
    The site's displayed revision identifier changed from v3.7.2 to v3.8.0; the study record page remains a 403 error.
    Difference
    0.2%
    Check dated 2026-11-01T01:36:01.000Z thumbnail image
  4. Check
    21 days ago
    Change Detected
    Summary
    A site-wide notice was added announcing an NIH website transition and explaining that both “Super Intelligence” and “Artificial Intelligence” may appear in NIH content.
    Difference
    1%
    Check dated 2026-10-25T01:27:56.000Z thumbnail image
  5. Check
    28 days ago
    Change Detected
    Summary
    The footer’s site revision changed from v3.7.1 to v3.7.2 while the page continued to display a 403 error.
    Difference
    0.2%
    Check dated 2026-10-18T01:13:05.000Z thumbnail image
  6. Check
    35 days ago
    Change Detected
    Summary
    The footer’s site revision label advances from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error instead of the study record.
    Difference
    0.2%
    Check dated 2026-10-11T01:48:10.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    The page now displays a 403 Forbidden error with the header and footer still visible. This replaces the previous study content and signals restricted access to the page.
    Difference
    21%
    Check dated 2026-09-20T00:25:13.000Z thumbnail image

Stay in the know with updates to Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Favezelimab+Pembrolizumab in Hematologic Malignancies Clinical Trial page.